Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study

P. Pozzilli, S. Manfrini, R. Buzzetti, E. Lampeter, I. De Leeuw, D. Iafusco, M. Prisco, C. Ionescu-Tirgoviste, S. Kolouskovà, T. Linn, J. Ludvigsson, L. Madàcsy, A. Seremak Mrozikiewicz, P. M. Mrozikiewicz, T. Podar, J. Vavrinec, B. Vialettes, N. Visalli, T. Yilmaz, P. D. Browne

Research output: Contribution to journalArticle

26 Citations (Scopus)


Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5-35 years), followed-up for a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA1c, blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6%) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA1c and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalDiabetes Research and Clinical Practice
Issue number3
Publication statusPublished - Jun 1 2005


  • Beta-cell destruction
  • Diabetes therapy
  • Insulin
  • Remission
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study'. Together they form a unique fingerprint.

  • Cite this

    Pozzilli, P., Manfrini, S., Buzzetti, R., Lampeter, E., Leeuw, I. D., Iafusco, D., Prisco, M., Ionescu-Tirgoviste, C., Kolouskovà, S., Linn, T., Ludvigsson, J., Madàcsy, L., Seremak Mrozikiewicz, A., Mrozikiewicz, P. M., Podar, T., Vavrinec, J., Vialettes, B., Visalli, N., Yilmaz, T., & Browne, P. D. (2005). Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study. Diabetes Research and Clinical Practice, 68(3), 258-264.